Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study

BMC Gastroenterology

Table 4 Odds ratios of abnormal liver function and NAFLD according to serum adipsin

	OR	95% CI	p value
Model 1
Elevated serum ALT	0.923	0.751–1.136	0.450
Elevated serum AST	1.047	0.705–1.554	0.821
Elevated serum GGT	0.917	0.775–1.086	0.316
NAFLD	0.850	0.752–0.961	0.010
Metabolic syndrome	1.027	0.905–1.165	0.680
Significant liver fibrosis by FIB-4	1.008	0.847–1.200	0.927
Model 2
Elevated serum ALT	0.863	0.687–1.083	0.203
Elevated serum AST	1.005	0.652–1.548	0.984
Elevated serum GGT	0.914	0.756–1.104	0.350
NAFLD	0.766	0.666–0.882	< 0.001
Metabolic syndrome	0.940	0.779–1.134	0.518
Significant liver fibrosis by FIB-4	1.038	0.866–1.244	0.687
Model 3
Elevated serum ALT	0.872	0.691–1.000	0.248
Elevated serum AST	1.016	0.653–1.581	0.944
Elevated serum GGT	0.916	0.757–1.109	0.370
NAFLD	0.783	0.679–0.902	< 0.001
Metabolic syndrome	0.968	0.800–1.170	0.733
Significant liver fibrosis by FIB-4	1.036	0.864–1.243	0.702

Model 1: adjusted for age, gender, smoking, alcohol consumption, and physical activity. Model 2: adjusted for model 1 + BMI, SBP, glucose, total cholesterol, triglyceride, and HDL-c. Model 3: adjusted for model 2 + HOMA-IR and body fat mass
OR = odds ratio; CI = confidence interval; BMI = body mass index; HOMA-IR = homeostasis model assessment of insulin resistance; FIB-4 = fibrosis-4 index

ISSN: 1471-230X